Polynovo Ltd

PNV

Company Profile

  • Business description

    Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.

  • Contact
  • Sector

    Healthcare

    Stock type

  • Industry

    Medical Devices

    Fiscal Year End

    Employees

Stocks News & Analysis

stocks

Will CEO departure upend ASX healthcare leader?

Turmoil with the board culuminates in the departure of the CEO.
stocks

One of the hottest shares on the ASX reports strong growth

Should investors chase this growth story or are they overvalued after the surge in the shares.  
stocks

An undervalued opportunity among ASX shares added to our coverage

Morningstar equity research initiates coverage on 3 ASX listed shares. 

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,053.20142.30-1.74%
CAC 407,790.71125.37-1.58%
DAX 4022,163.49298.03-1.33%
Dow JONES (US)42,000.28416.381.00%
FTSE 1008,582.8176.04-0.88%
HKSE23,119.58307.02-1.31%
NASDAQ17,263.9659.03-0.34%
Nikkei 22535,617.561,502.77-4.05%
NZX 50 Index12,270.0017.46-0.14%
S&P 5005,605.8024.860.45%
S&P/ASX 2007,843.40138.60-1.74%
SSE Composite Index3,335.7515.56-0.46%

Market Movers